These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 11034329)

  • 1. N-terminal and core-domain random mutations in human topoisomerase II alpha conferring bisdioxopiperazine resistance.
    Jensen LH; Wessel I; Møller M; Nitiss JL; Sehested M; Jensen PB
    FEBS Lett; 2000 Sep; 480(2-3):201-7. PubMed ID: 11034329
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Chinese hamster ovary cells resistant to the topoisomerase II catalytic inhibitor ICRF-159: a Tyr49Phe mutation confers high-level resistance to bisdioxopiperazines.
    Sehested M; Wessel I; Jensen LH; Holm B; Oliveri RS; Kenwrick S; Creighton AM; Nitiss JL; Jensen PB
    Cancer Res; 1998 Apr; 58(7):1460-8. PubMed ID: 9537249
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Probing the interaction of the cytotoxic bisdioxopiperazine ICRF-193 with the closed enzyme clamp of human topoisomerase IIalpha.
    Patel S; Jazrawi E; Creighton AM; Austin CA; Fisher LM
    Mol Pharmacol; 2000 Sep; 58(3):560-8. PubMed ID: 10953049
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Human small cell lung cancer NYH cells selected for resistance to the bisdioxopiperazine topoisomerase II catalytic inhibitor ICRF-187 demonstrate a functional R162Q mutation in the Walker A consensus ATP binding domain of the alpha isoform.
    Wessel I; Jensen LH; Jensen PB; Falck J; Rose A; Roerth M; Nitiss JL; Sehested M
    Cancer Res; 1999 Jul; 59(14):3442-50. PubMed ID: 10416608
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Probing the role of linker substituents in bisdioxopiperazine analogs for activity against wild-type and mutant human topoisomerase II alpha.
    Renodon-Cornière A; Sørensen TK; Jensen PB; Nitiss JL; Søkilde B; Sehested M; Jensen LH
    Mol Pharmacol; 2003 May; 63(5):1159-68. PubMed ID: 12695544
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Interaction of human DNA topoisomerase II alpha with DNA: quantification by surface plasmon resonance.
    Renodon-Cornière A; Jensen LH; Nitiss JL; Jensen PB; Sehested M
    Biochemistry; 2002 Nov; 41(45):13395-402. PubMed ID: 12416984
    [TBL] [Abstract][Full Text] [Related]  

  • 7. DNA topoisomerase II is the molecular target of bisdioxopiperazine derivatives ICRF-159 and ICRF-193 in Saccharomyces cerevisiae.
    Ishida R; Hamatake M; Wasserman RA; Nitiss JL; Wang JC; Andoh T
    Cancer Res; 1995 Jun; 55(11):2299-303. PubMed ID: 7757979
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Selection of human leukemic CEM cells for resistance to the DNA topoisomerase II catalytic inhibitor ICRF-187 results in increased levels of topoisomerase IIalpha and altered G(2)/M checkpoint and apoptotic responses.
    Morgan SE; Cadena RS; Raimondi SC; Beck WT
    Mol Pharmacol; 2000 Feb; 57(2):296-307. PubMed ID: 10648639
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A novel mechanism of cell killing by anti-topoisomerase II bisdioxopiperazines.
    Jensen LH; Nitiss KC; Rose A; Dong J; Zhou J; Hu T; Osheroff N; Jensen PB; Sehested M; Nitiss JL
    J Biol Chem; 2000 Jan; 275(3):2137-46. PubMed ID: 10636919
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Separation of bisdioxopiperazine- and vanadate resistance in topoisomerase II.
    Sorensen TK; Grauslund M; Jensen PB; Sehested M; Jensen LH
    Biochem Biophys Res Commun; 2005 Sep; 334(3):853-60. PubMed ID: 16053917
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Analysis of bisdioxopiperazine dexrazoxane binding to human DNA topoisomerase II alpha: decreased binding as a mechanism of drug resistance.
    Renodon-Cornière A; Jensen LH; Nitiss JL; Jensen PB; Sehested M
    Biochemistry; 2003 Aug; 42(32):9749-54. PubMed ID: 12911317
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mutations at arg486 and glu571 in human topoisomerase IIalpha confer resistance to amsacrine: relevance for antitumor drug resistance in human cells.
    Patel S; Keller BA; Fisher LM
    Mol Pharmacol; 2000 Apr; 57(4):784-91. PubMed ID: 10727526
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Characterization of a Chinese hamster ovary cell line with acquired resistance to the bisdioxopiperazine dexrazoxane (ICRF-187) catalytic inhibitor of topoisomerase II.
    Hasinoff BB; Kuschak TI; Creighton AM; Fattman CL; Allan WP; Thampatty P; Yalowich JC
    Biochem Pharmacol; 1997 Jun; 53(12):1843-53. PubMed ID: 9256159
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Characterisation of cytotoxicity and DNA damage induced by the topoisomerase II-directed bisdioxopiperazine anti-cancer agent ICRF-187 (dexrazoxane) in yeast and mammalian cells.
    Jensen LH; Dejligbjerg M; Hansen LT; Grauslund M; Jensen PB; Sehested M
    BMC Pharmacol; 2004 Dec; 4():31. PubMed ID: 15575955
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Human small cell lung cancer NYH cells resistant to the bisdioxopiperazine ICRF-187 exhibit a functional dominant Tyr165Ser mutation in the Walker A ATP binding site of topoisomerase II alpha.
    Wessel I; Jensen LH; Renodon-Corniere A; Sorensen TK; Nitiss JL; Jensen PB; Sehested M
    FEBS Lett; 2002 Jun; 520(1-3):161-6. PubMed ID: 12044890
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Decreased topoisomerase IIalpha expression confers increased resistance to ICRF-193 as well as VP-16 in mouse embryonic stem cells.
    Kobayashi M; Adachi N; Aratani Y; Kikuchi A; Koyama H
    Cancer Lett; 2001 May; 166(1):71-7. PubMed ID: 11295289
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Collateral sensitivity to the bisdioxopiperazine dexrazoxane (ICRF-187) in etoposide (VP-16)-resistant human leukemia K562 cells.
    Fattman CL; Allan WP; Hasinoff BB; Yalowich JC
    Biochem Pharmacol; 1996 Aug; 52(4):635-42. PubMed ID: 8759037
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Characterization of the biological and biochemical activities of F 11782 and the bisdioxopiperazines, ICRF-187 and ICRF-193, two types of topoisomerase II catalytic inhibitors with distinctive mechanisms of action.
    van Hille B; Etiévant C; Barret JM; Kruczynski A; Hill BT
    Anticancer Drugs; 2000 Nov; 11(10):829-41. PubMed ID: 11142691
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mapping of DNA topoisomerase II poisons (etoposide, clerocidin) and catalytic inhibitors (aclarubicin, ICRF-187) to four distinct steps in the topoisomerase II catalytic cycle.
    Sehested M; Jensen PB
    Biochem Pharmacol; 1996 Apr; 51(7):879-86. PubMed ID: 8651936
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Differential expression of topoisomerase I and RAD52 protein in yeast reveals new facets of the mechanism of action of bisdioxopiperazine compounds.
    van Hille B; Clerc X; Creighton AM; Hill BT
    Br J Cancer; 1999 Nov; 81(5):800-7. PubMed ID: 10555749
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.